Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 21 of 21
Full-Text Articles in Engineering
Vaccine Technology Ii: Abstracts Of Poster Presentations, The Editors
Vaccine Technology Ii: Abstracts Of Poster Presentations, The Editors
Vaccine Technology II
No abstract provided.
Vaccine Technology Ii: Abstracts Of Oral Presentations, The Editors
Vaccine Technology Ii: Abstracts Of Oral Presentations, The Editors
Vaccine Technology II
No abstract provided.
Process Intensification For Large Scale Manufacturing Issues, J.C. Drugmand, N. Havelange, N. Alaoui, J. Castillo
Process Intensification For Large Scale Manufacturing Issues, J.C. Drugmand, N. Havelange, N. Alaoui, J. Castillo
Vaccine Technology II
No abstract provided.
Analytical And Manufacturing Challenges In Preparation Of Bacterial Polysaccharide Conjugates, Carl Frasch
Analytical And Manufacturing Challenges In Preparation Of Bacterial Polysaccharide Conjugates, Carl Frasch
Vaccine Technology II
No abstract provided.
Veev Replicon-Based Vaccines Used In Heterologous Prime Boost Strategies Induce Lifelong Protection Against Prostate Cancer And Therapy Of Cervical Cancer In Mice And Robust Cell-Mediated Immunity In Rhesus Macaques, W. Martin Kast
Vaccine Technology II
No abstract provided.
Focus On Aggregation: Causes, Impact & Characterization, John Philo
Focus On Aggregation: Causes, Impact & Characterization, John Philo
Vaccine Technology II
No abstract provided.
Flublok, A High Dose Recombinant Hemagglutinin Influenza Vaccine, Manon Cox
Flublok, A High Dose Recombinant Hemagglutinin Influenza Vaccine, Manon Cox
Vaccine Technology II
No abstract provided.
Towards A Therapeutic Hepatitis C Vaccine – A Preclinical And Clinical Learning Curve, Alexander Von Gabain
Towards A Therapeutic Hepatitis C Vaccine – A Preclinical And Clinical Learning Curve, Alexander Von Gabain
Vaccine Technology II
No abstract provided.
Rsv Vaccine Using Recombinant F Protein?, Sophie Nallet
Rsv Vaccine Using Recombinant F Protein?, Sophie Nallet
Vaccine Technology II
No abstract provided.
Development Of Vaxfectin®-Adjuvanted Dna Vaccines, Alain Rolland
Development Of Vaxfectin®-Adjuvanted Dna Vaccines, Alain Rolland
Vaccine Technology II
No abstract provided.
Quality Issues: The Good-Enough Vaccine, Philip Minor
Quality Issues: The Good-Enough Vaccine, Philip Minor
Vaccine Technology II
No abstract provided.
Challenges And Solutions For The Next Generation Of Vaccines: Development Of Cell Culture-Based Live Attenuated Influenza Vaccine, Jonathan Liu, Luis Maranga, Sachin Mani, Richard Schwartz
Challenges And Solutions For The Next Generation Of Vaccines: Development Of Cell Culture-Based Live Attenuated Influenza Vaccine, Jonathan Liu, Luis Maranga, Sachin Mani, Richard Schwartz
Vaccine Technology II
No abstract provided.
Development Of Validated Assays For Measuring The Human Antibody Response To Polysaccharide Conjugate Vaccines, Helena Käyhty
Development Of Validated Assays For Measuring The Human Antibody Response To Polysaccharide Conjugate Vaccines, Helena Käyhty
Vaccine Technology II
No abstract provided.
Challenge Of Filing 4 New Vaccines At Once – Lessons Learned, Keith Chirgwin
Challenge Of Filing 4 New Vaccines At Once – Lessons Learned, Keith Chirgwin
Vaccine Technology II
No abstract provided.
Emerging Diseases, Zoonoses And Vaccines To Control Them, Paul-Pierre Pastoret
Emerging Diseases, Zoonoses And Vaccines To Control Them, Paul-Pierre Pastoret
Vaccine Technology II
No abstract provided.
Vaccine Technology Ii: Conference Program, Barry C. Buckland, John G. Auniņš, Paula Marques Alves, Kathrin U. Jansen
Vaccine Technology Ii: Conference Program, Barry C. Buckland, John G. Auniņš, Paula Marques Alves, Kathrin U. Jansen
Vaccine Technology II
No abstract provided.
Trouble-Shooting Fermentation And Primary Recovery Manufacturing Issues In Order To Optimize Antigen Expression For The Vaccine Business, Tim Lee
Vaccine Technology II
No abstract provided.
Developing Vaccines For Neglected Diseases, Douglas Holtzman
Developing Vaccines For Neglected Diseases, Douglas Holtzman
Vaccine Technology II
No abstract provided.
Vaccine Development For Developing Countries – Regulatory Approach In The European Union, Manfred G. Haase
Vaccine Development For Developing Countries – Regulatory Approach In The European Union, Manfred G. Haase
Vaccine Technology II
No abstract provided.
A Selective Recovery Methodology For The Primary Purification Of Lipid Envelope Virus-Like Particles From S. Cerevisiae, Gaik Sui Kee, Hari Pujar, Nigel Titchener-Hooker
A Selective Recovery Methodology For The Primary Purification Of Lipid Envelope Virus-Like Particles From S. Cerevisiae, Gaik Sui Kee, Hari Pujar, Nigel Titchener-Hooker
Vaccine Technology II
No abstract provided.
Well-Characterized Adenoviral Vector-Based Vaccines: Are We There Yet?, Katey Einterz Owen
Well-Characterized Adenoviral Vector-Based Vaccines: Are We There Yet?, Katey Einterz Owen
Vaccine Technology II
No abstract provided.